Xanthinuria type II is a rare genetic condition that affects how the body breaks down certain purines. People with xanthinuria type II often have very low uric acid and high xanthine in blood and urine. This can lead to kidney stones, urinary pain, or blood in the urine, but some people have no signs. It is lifelong and usually recognized in childhood or adulthood when stones or abnormal lab results appear. Treatment focuses on prevention with high fluid intake, a low-purine diet, and monitoring, and most people have a normal life span if kidney health is protected.
Overview
Xanthinuria type iiSymptoms
Many people with Xanthinuria type II have no symptoms. When features occur, they usually come from xanthine kidney stones—side or back pain, blood in urine, urinary urgency, infections—and doctors may find very low uric acid on tests.
Outlook and prognosis
Most people with Xanthinuria type II remain well and learn about it after routine tests show very low uric acid. Kidney stones can occur but are preventable with high fluid intake and diet guidance. With monitoring, long‑term outlook is generally excellent.
Causes and risk factors
Xanthinuria type II results from inherited changes in the MOCOS gene, causing autosomal recessive enzyme deficiency. Risk is higher with two carrier parents or consanguinity. Low fluid intake and high‑purine diets can aggravate stone formation risk.
Genetic influences
Genetics are central in Xanthinuria type II. It results from inherited changes that disrupt how the body breaks down purines, causing excess xanthine. Most cases are autosomal recessive, so parents are usually carriers; family testing and genetic counseling can help.
Diagnosis
Doctors suspect Xanthinuria type ii when kidney stones occur early and blood uric acid is very low. Diagnosis is confirmed by high xanthine in urine, imaging of stones, and genetic tests; this is the genetic diagnosis of Xanthinuria type ii.
Treatment and drugs
Treatment for Xanthinuria type II focuses on lowering xanthine buildup and protecting kidney health. Many follow a low‑purine eating plan, drink plenty of fluids, and sometimes use urine alkalinization; kidney stones may need urology procedures. Regular monitoring guides adjustments.
Symptoms
Many people with Xanthinuria type ii feel well for years. The condition leads to very low uric acid and a buildup of xanthine, which can form stones in the kidneys and urinary tract, cause blood in the urine, or trigger cramping flank pain. Features vary from person to person and can change over time. Early features of Xanthinuria type ii often show up in the bathroom: cloudy urine, gritty crystals, or burning when passing urine.
Stones made mostly of xanthine can form in the kidneys or ureters. In Xanthinuria type ii, these stones can cause sudden, severe pain in the side or back that may spread to the lower belly or groin. Nausea or vomiting can happen during a pain attack.
You may see pink, red, or tea-colored urine. Sometimes it's only seen on a urine test.
Urine can look cloudy, and some notice sandy or gritty particles in the toilet. This comes from xanthine crystals passing into the urine.
Passing urine can sting or burn when crystals or stones irritate the urinary tract. You may feel a frequent urge to go, even when only a small amount comes out.
How people usually first notice Xanthinuria type ii?
Many people first notice xanthinuria type II when they pass kidney stones at a young age, often with sudden flank pain, blood in the urine, or recurrent urinary tract symptoms despite drinking normally. Doctors may also pick it up after routine urine tests show very low uric acid and unusually high xanthine, prompting genetic testing to confirm the diagnosis. In infants or children, the first signs of xanthinuria type II can be unexplained urinary issues or stones seen on imaging, leading families to seek care for how xanthinuria type II is first noticed.
Types of Xanthinuria type ii
Xanthinuria type II is a rare inherited condition. There are no widely accepted subtypes within type II itself; the “types” of xanthinuria generally refer to type I versus type II (and occasionally type III in some literature). People with xanthinuria can have very different day‑to‑day experiences—some feel well, while others develop kidney stones or muscle aches. When people search for “types of Xanthinuria type ii,” they’re usually comparing type I and type II, which differ by the enzyme steps affected and may show slightly different lab patterns but similar symptoms.
Type I xanthinuria
Caused by loss of xanthine dehydrogenase activity alone. Symptoms often mirror type II, with xanthine kidney stones, urinary discomfort, or muscle pains after activity. Lab tests show very low uric acid with high xanthine and hypoxanthine.
Type II xanthinuria
Caused by loss of both xanthine dehydrogenase and aldehyde oxidase activities. Day‑to‑day symptoms are similar to type I, but milk ingestion tests and certain drug‑metabolism clues can differ. Some may have additional sensitivity to medications that need aldehyde oxidase to break down.
Type III (rare)
Reported rarely and variably in the literature. Features overlap with types I and II, and consensus criteria are limited. Not everyone will experience every type.
What genetics can tell you about symptoms
In xanthinuria type II, changes in the XDH and MOCOS genes reduce two enzymes that normally process purines, causing xanthine to build up. This buildup can lead to kidney stones, blood in urine, painful urination, and sometimes joint pain or muscle cramps.
Causes and risk factors
Xanthinuria type ii is caused by inherited changes in a gene called MOCOS, which keep two enzymes that break down purines from working properly. It is usually passed down when both parents carry the same gene change. Genes set the stage, but environment and lifestyle often decide how the story unfolds. Dehydration, low urine volume, and a very high purine diet can raise xanthine levels and increase the chance of kidney stones or muscle pain. Family history can raise the chance of being a carrier, and heavy exercise or illness with dehydration can bring on early symptoms of xanthinuria type ii.
Environmental and biological risk factors
Xanthinuria type ii is present from birth, and current evidence points to risks rooted in early biology rather than outside exposures. There are no proven environmental or pregnancy-related factors that raise the chance of having it, and there are no environmental predictors of the early symptoms of Xanthinuria type ii. Researchers are still exploring how outside influences interact with our inner biology. Here’s what is and isn’t known about environmental and biological risk factors.
Older maternal or paternal age has not been shown to increase the likelihood of this condition. Available reports do not show an age-related pattern.
Common conditions such as diabetes, high blood pressure, or infections during pregnancy have not been linked to this condition. Current evidence does not show these factors raise risk.
No specific prescription or over-the-counter medicines in pregnancy are proven to cause Xanthinuria type ii. Some drugs can temporarily affect related enzymes, but they do not create this congenital condition.
Exposure to heavy metals, pesticides, or air pollution has not been shown to raise risk. Studies to date do not connect these exposures to this condition.
Genetic risk factors
Understanding the genetic roots helps families plan and supports early diagnosis. In Xanthinuria type ii, changes in a single gene disrupt enzymes that process purines; genetic testing for Xanthinuria type ii can confirm the specific change. Some risk factors are inherited through our genes.
MOCOS gene variants: Changes in the MOCOS gene are the direct cause of Xanthinuria type ii. Both copies must carry a harmful change for the condition to appear.
Autosomal recessive pattern: Xanthinuria type ii follows an autosomal recessive pattern. A child must inherit two changed copies—one from each parent—to be affected. Each pregnancy of two carrier parents has a 25% (1 in 4) chance.
Carrier parents: Carriers have one changed MOCOS copy and usually have no symptoms. Two carriers can have a child with Xanthinuria type ii. Siblings of someone affected often have a higher chance of being carriers.
Family history: A known MOCOS change or affected sibling raises risk for close relatives. If one child is affected, future pregnancies have the same 25% (1 in 4) risk.
Parental relatedness: When parents are related by blood, they are more likely to share the same MOCOS change. This increases the chance their children will inherit two changed copies.
Founder variants: In some families or communities, a specific MOCOS change can be more common due to a founder effect. This can cluster cases of Xanthinuria type ii within that group.
Lifestyle risk factors
Xanthinuria type ii is a genetic condition; lifestyle habits do not cause it, but they can influence symptoms and complications. In particular, diet, hydration, and activity patterns affect xanthine production, urine concentration, and stone risk. Understanding how lifestyle affects Xanthinuria type ii can help tailor everyday choices to reduce kidney stones and muscle symptoms. Below are practical elements often discussed by clinicians as lifestyle risk factors for Xanthinuria type ii.
Eating organ meats, certain fish, and yeast-rich foods increases purine load, which converts to xanthine when the enzymes are deficient. This can raise xanthine levels and promote kidney stone formation. A lower-purine pattern reduces xanthine production.
Low fluid intake concentrates urine, making xanthine more likely to crystallize. Consistent high water intake dilutes xanthine and supports stone prevention.
Diets high in animal protein and low in fruits and vegetables acidify urine, where xanthine is less soluble. Shifting toward more alkaline-forming foods may improve xanthine solubility and reduce stone risk. Diet can complement any urine-alkalinizing therapy your clinician recommends.
Strenuous, prolonged workouts increase ATP turnover and purine breakdown, which can raise xanthine production. Combined with sweat losses, this can trigger stone risk or muscle pain. Moderate activity with planned hydration is usually safer.
Risk prevention
Xanthinuria type ii is a rare inherited condition where the body builds up xanthine, which can form kidney stones and strain the kidneys. You can’t prevent the condition itself, but you can lower the chance of stones and kidney problems by managing daily habits and medical follow-up. Prevention works best when combined with regular check-ups. Knowing early symptoms of Xanthinuria type ii, like sudden side or back pain or blood in the urine, helps you act quickly.
Drink enough fluids to keep urine light in color most of the day. Many aim for about 2.5–3 liters (85–100 oz) daily, and more during heat, exercise, or illness if your doctor says it’s safe.
Limit high‑purine foods such as organ meats and certain fish (like anchovies and sardines). Favor beans, dairy, eggs, and moderate portions of other proteins, and consider a dietitian for practical swaps.
Do not use xanthine‑oxidase inhibitors (like allopurinol or febuxostat) unless a specialist clearly advises it. Ask your clinicians to review medicines that rely on aldehyde oxidase, since these may build up in type ii.
Your doctor may recommend potassium citrate or similar treatments to make urine less acidic, which can reduce crystal formation. Don’t start alkalinizing agents without medical guidance.
Transmission
Xanthinuria type ii is a genetic condition, not an infection, so it can’t be caught from someone else and isn’t spread by touch, coughing, sex, blood, or food. The genetic transmission of Xanthinuria type ii follows an autosomal recessive pattern: most often, both parents carry one nonworking copy of the gene but are healthy themselves. When two carriers have a child, there’s a 25% chance the child will have Xanthinuria type ii, a 50% chance the child will be a carrier like the parents, and a 25% chance the child will inherit neither nonworking copy. If this pattern may apply to your family, a genetics professional can explain how Xanthinuria type ii is inherited and discuss testing for relatives.
When to test your genes
Xanthinuria type II is a rare inherited condition; consider genetic testing if you have unexplained kidney stones, very low uric acid, or excess xanthine in urine, especially with a family history. Test before pregnancy or certain medications to tailor care and avoid stone‑promoting drugs. A genetics consult can guide timing and impact.
Diagnosis
You might notice small changes in daily routines, like passing kidney stones despite drinking plenty of water or being told your uric acid level is surprisingly low on a routine blood test. For many, these clues prompt a closer look for Xanthinuria type II, a rare condition present from birth that affects how the body handles certain building blocks of DNA. The genetic diagnosis of Xanthinuria type ii usually combines lab findings with confirmatory testing. Genetic testing may be offered to clarify risk or guide treatment.
Repeated kidney stones, especially in childhood or early adulthood, raise suspicion. Very low uric acid can be a key early sign. Muscle aches after exercise may also occur.
A blood test often shows very low uric acid levels. Urine tests show low uric acid but high xanthine and hypoxanthine. Specialized labs can quantify these compounds.
A technician may see xanthine crystals under the microscope. These crystals look different from common uric acid crystals. Findings support the diagnosis when paired with low uric acid.
If a stone is passed or removed, the lab can identify xanthine using infrared spectroscopy. This confirms the stone’s composition and helps distinguish it from uric acid stones. Knowing the stone type guides prevention.
Stages of Xanthinuria type ii
Xanthinuria type ii does not have defined progression stages. It’s a lifelong metabolic condition present from birth; symptoms often don’t follow a steady decline and may come and go, mainly when crystals or stones form in the urinary tract. Different tests may be suggested to help confirm the diagnosis, including very low blood uric acid, high xanthine in urine or stones, and genetic testing of the MOCOS gene. Doctors usually monitor with urinalysis, kidney imaging (ultrasound), and kidney function blood tests over time; early symptoms of Xanthinuria type ii can be silent or show up as blood in urine, flank pain, or frequent stones.
Outlook and prognosis
Looking at the long-term picture can be helpful. For most people with Xanthinuria type II, the outlook is generally favorable, especially when the condition is recognized early and kidney health is protected. Many people have few or no symptoms day to day, and some only learn about the condition after unusual blood or urine test results. Early symptoms of Xanthinuria type II can include passing kidney stones, flank pain, or urinary urgency, but some never develop stones at all.
The outlook is not the same for everyone, but most people maintain normal life expectancy when they stay hydrated and follow prevention advice from their care team. The main risk over time is kidney and urinary tract stone formation, which can lead to infections or, rarely, kidney damage if stones keep recurring. Your clinician may suggest a high-fluid intake, urine alkalinization, and avoiding very high purine loads from diet or supplements to reduce stone risk. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle.
Understanding the prognosis can guide planning and help you spot warning signs early—new flank pain, blood in the urine, fevers with urinary symptoms, or trouble passing urine deserve prompt care. With ongoing care, many people maintain good kidney function without major complications. There is no known increase in overall mortality directly from Xanthinuria type II when kidney health is preserved. Talk with your doctor about what your personal outlook might look like, including how often to monitor kidney function and what to do if symptoms change.
Long-term effects
For many living with Xanthinuria type ii, the long-term picture ranges from no issues to recurring kidney stone problems. People may not notice early symptoms of Xanthinuria type ii, and it’s often found through very low uric acid on blood tests or xanthine in the urine. Long-term effects vary widely, and many people remain well with careful monitoring. Some may face kidney-related complications or differences in how certain medicines are processed over time.
Many people have no day-to-day problems for years. Xanthinuria type ii may only be noticed on lab tests showing very low uric acid.
Crystals can form stones that cause flank or abdominal pain. Stones may recur over time in Xanthinuria type ii.
Tiny crystals in urine can sometimes clump and block urine flow. This can lead to sudden difficulty passing urine or discomfort.
Repeated stones or blockages can strain the kidneys over years. Some develop chronic kidney changes if episodes are frequent or severe.
How is it to live with Xanthinuria type ii?
Living with xanthinuria type II often means feeling well day to day but needing steady attention to hydration and diet to prevent kidney stones and muscle discomfort after strenuous activity. Many learn to limit purine‑rich foods and caffeine, drink plenty of fluids, and check in periodically with a clinician to monitor kidneys and muscles, which helps keep complications rare. Family members and friends can be supportive by normalizing these routines—planning water breaks, choosing flexible meal options, and understanding that someone may pause activity if cramps or fatigue appear. With a few practical habits and shared awareness, most people lead full, active lives without major limitations.
Treatment and drugs
Treatment for xanthinuria type II focuses on preventing kidney stones and protecting kidney function, since the body has trouble breaking down xanthine and hypoxanthine. Most people are advised to drink plenty of fluids (aim for at least 2–3 liters, or about 68–101 oz, per day unless your doctor says otherwise) and follow a low‑purine eating plan to lower xanthine levels; a dietitian can help make this practical. There’s no specific drug that corrects the enzyme problem, and allopurinol is usually avoided because it can raise xanthine further, but pain control and procedures to remove stones may be used if blockages occur. Ultrasound or other imaging may be checked regularly, and urine tests can help track stone risk over time. Your doctor can help weigh the pros and cons of each option.
Non-drug treatment
Living with Xanthinuria type ii often comes down to daily choices that protect your kidneys and lower the chance of stone formation. Drinking enough fluids, choosing lower‑purine foods, and keeping urine less acidic can make a real difference. Non-drug treatments often lay the foundation for long‑term kidney health and can complement any medical care you receive. Planning for hot days, exercise, and illness helps you stay ahead of dehydration and symptoms.
Choose lean proteins in modest portions and favor plant‑based meals to reduce xanthine build‑up. Limit organ meats, certain fish like anchovies and sardines, and meat broths.
Aim for at least 2–3 liters (about 68–101 oz) of fluids daily unless your doctor advises otherwise. Spread drinks across the day and add an extra glass with meals and exercise.
Emphasize fruits and vegetables, and consider citrus drinks like lemon or lime water to help keep urine less acidic. This can support xanthine solubility in Xanthinuria type ii.
Choose steady, moderate activity and build up gradually to avoid muscle discomfort linked to xanthine deposits. Hydrate before, during, and after workouts, especially in hot weather.
Your genes may have an impact on how drugs work for you
Some medicines are handled by enzymes that the XDH and MOCOS genes help control, so gene changes in xanthinuria type II can alter how fast drugs are processed or cleared. This means standard doses might be too strong, too weak, or risk side effects.
Pharmacological treatments
For most people living with Xanthinuria type ii, medicine focuses on preventing kidney stones and managing pain during stone episodes. Because early symptoms of Xanthinuria type ii can be easy to miss, the aim is to keep crystals from forming and help small stones pass if they occur. Drug choices are limited since the enzyme that normally handles certain medicines is reduced or absent in this condition. Not everyone responds to the same medication in the same way.
This alkalinizes urine and may modestly improve xanthine solubility to lower stone risk. Doses are individualized and urine pH is often monitored to guide adjustments.
This is another urine-alkalinizing option if citrate is not tolerated. It can raise urinary pH but may cause bloating or sodium load, so monitoring is important.
This can relax the ureter to help small stones pass more easily during an acute episode. It is usually used short term alongside fluids and pain relief.
Ibuprofen or diclofenac can ease renal colic pain and reduce inflammation. Use the lowest effective dose and check kidney function if pain is severe or prolonged.
Genetic influences
In most families, xanthinuria type II happens because of changes in a single gene called MOCOS. This gene helps activate enzymes that break down natural body chemicals called purines; when it doesn’t work properly, xanthine can build up and uric acid levels fall. Some conditions are passed down through families (inherited disorders). Xanthinuria type II is usually inherited in an autosomal recessive pattern, meaning a child needs two nonworking copies—one from each parent—to develop the condition. Parents who each carry one gene change typically stay healthy, but they have a 1 in 4 (25%) chance with each pregnancy of having a child with xanthinuria type II. Learning how xanthinuria type II is inherited can help you and your care team decide whether carrier testing or targeted genetic testing of the MOCOS gene would be useful for your family.
Is Xanthinuria type ii genetic?
Genetics are central in Xanthinuria type II. It results from inherited changes that disrupt how the body breaks down purines, causing excess xanthine. Most cases are autosomal recessive, so parents are usually carriers; family testing and genetic counseling can help.
Pharmacogenetics—how genetics influence drug effects
In Xanthinuria type ii, the same inherited change that lowers uric acid also leaves two drug‑processing enzymes—xanthine oxidase and aldehyde oxidase—working poorly or not at all. Because of this, medicines that block xanthine oxidase, such as allopurinol or febuxostat for gout, don’t help and are usually avoided. Thiopurine drugs used in some autoimmune conditions and cancers (azathioprine and 6‑mercaptopurine) rely on these pathways to be broken down; when the enzymes are missing, levels can build up and raise the risk of side effects, so doctors may choose alternatives or use much lower doses with close blood monitoring. Type ii also reduces aldehyde oxidase activity, so certain antivirals or sleep medicines that depend on it may work unpredictably; your pharmacist can help flag safer options. Genetic testing can sometimes identify how your body handles these medicines and guide safer dosing choices. Whenever a new prescription is considered, let your clinicians know you’re living with Xanthinuria type ii so they can check for drug–gene interactions before you start it.
Interactions with other conditions
People with Xanthinuria type ii often deal with kidney stone issues, so anything that stresses the urinary tract—like dehydration, vigorous exercise, or a urinary tract infection—can make symptoms flare. Doctors call it a “comorbidity” when two conditions occur together, and kidney or bladder problems can increase the chance of blockage or pain from xanthine stones. If gout also happens to be present, standard uric acid–lowering treatments may not be helpful here because uric acid is already unusually low in Xanthinuria type ii, so care plans usually need tailoring. Some medicines are processed by an enzyme that’s also reduced in this condition, which means certain drugs may either build up or not work as expected; this is especially relevant if you take multiple prescriptions. Ask if any medications for one condition might interfere with treatment for another. During a UTI or a period of heavy sweating, early symptoms of Xanthinuria type ii—such as side or back pain from passing stones—can become more noticeable, so extra fluids and prompt care often help.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described unexplained kidney stones and sandy, orange-brown crystals in urine, especially in children and young adults who otherwise felt well. Families sometimes noticed that several relatives developed stones early or had urine that stained diapers or pots, hinting at an inherited pattern long before anyone knew the chemistry behind it. Doctors could see the stones and crystals, but the exact cause remained unclear.
First described in the medical literature as a form of “xanthine stone disease,” Xanthinuria type II was initially grouped with other rare stone disorders. Early case reports focused on symptoms—repeated kidney colic, urinary crystals, and occasional muscle aches after exercise—rather than the root problem. Over time, careful analysis of stones showed they were made of xanthine, not the more common uric acid. This led researchers to measure the body’s purine breakdown products and to notice that xanthine built up while uric acid stayed unusually low.
Building on this early work, scientists teased apart different subtypes. What set Xanthinuria type II apart was that two liver enzymes involved in purine processing were affected, not just one. As laboratory methods improved in the late 20th century, enzyme testing and later gene studies clarified that type II involves both xanthine dehydrogenase and aldehyde oxidase. This explained why some people with Xanthinuria type II had slightly broader metabolic findings than those with type I, even if day-to-day symptoms overlapped.
Advances in genetics confirmed the inherited nature of Xanthinuria type II and helped families understand why it can appear in siblings born to healthy parents. Researchers identified changes in the gene that helps build the molybdenum cofactor, a small helper molecule that these enzymes need to work. With this insight, doctors could move from describing unusual stones to offering targeted testing: checking urine for very low uric acid, high xanthine, and, when available, enzyme or genetic assays to distinguish between type I and type II.
Despite evolving definitions, the practical lessons from this history are steady. Many living with Xanthinuria type II feel well until a stone causes pain, so recognition often starts with urology visits rather than metabolic clinics. Knowing the condition’s history can explain why some older reports used different names and why modern care emphasizes hydration, a reduced purine diet, and avoiding certain drugs that rely on the affected enzymes. Today, Xanthinuria type II is better recognized, even if still rare, and its story reflects how careful observation, chemistry, and genetics came together to reshape diagnosis and care.